The goal will be to attack each tumor, rather than with a single therapeutic antibody recognizing antigens in the surface of the tumor cell, as is the case for most tumors (i.e., HER2+ tumors treated with trastuzumab, pertuzumab, or their derivatives), with an appropriate combination of antibodies, preferentially recognizing different antigens or different epitopes of the same antigen expressed on the tumor cell surface, as initially demonstrated with the combination of trastuzumab and pertuzumab with docetaxel for the treatment of patients with HER2-amplified metastatic breast cancer [112]. The gene discussed is ERBB2; the disease is neoplasm.